The global contraceptive drugs market size attained a value of USD 17.42bn in 2022. The market is further expected to grow at a CAGR of 7.02% during the forecast period of 2023-2031 to attain a value of USD 32.08bn by 2031.
The growth of the market is driven by the increasing awareness and acceptance of contraceptive drugs.
Contraceptive drugs are medications that are used to prevent unwanted pregnancies by suppressing ovulation, altering the cervical mucus to prevent sperm from reaching the egg, or changing the lining of the uterus to prevent implantation.
These drugs are available in different forms such as pills, patches, injections, vaginal rings, and implants.
There are two main types of contraceptive drugs: hormonal and non-hormonal. Hormonal contraceptive drugs contain synthetic versions of the female hormones oestrogen and progestin, or progestin alone, which work by inhibiting ovulation.
Non-hormonal contraceptive drugs, on the other hand, work by altering the acidity of the cervical mucus or by creating a physical barrier that prevents sperm from reaching the egg.
Contraceptive drugs are widely used by women around the world to prevent unwanted pregnancies and to space out births.
They are a safe and effective method of birth control when used correctly, but like any medication, they can have side effects.
It is important to talk to a healthcare provider to determine the best contraceptive option based on an individual's medical history, lifestyle, and preferences.
The global contraceptive drugs market is expected to experience steady growth in the coming years. This market is driven by the increasing awareness and acceptance of contraceptive drugs as a means of birth control, especially among women.
The market is expected to be driven by various factors such as an increase in the prevalence of unwanted pregnancies and sexually transmitted diseases, a rise in the number of women in the workforce, and an increase in the availability of contraceptive drugs.
Additionally, technological advancements, such as the development of new drugs with fewer side effects, are expected to drive market growth.
Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The Asia Pacific region is expected to experience the highest growth in the market due to the high population growth rate and increasing awareness of contraceptive drugs among women.
Overall, the global contraceptive drugs market is expected to experience steady growth in the coming years, driven by increasing awareness, technological advancements, and the introduction of new and improved drugs.
The report gives an in-depth analysis of the key players involved in the contraceptive drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals.
The companies included in the market are as follows:
Piramal Enterprises Ltd
Agile Therapeutics
Johnson & Johnson Services, Inc
Abbive Inc
Merck & Co Inc
Teva Pharmaceuticals Industries Ltd
Bayer AG
Pfizer Inc
Helm AG
Reckitt Benckiser Group PLC
Viatris Inc
Amneal Pharmaceuticals LLC
Bayer AG
Allergan plc
Agile Therapeutics
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI